RxDoctor Payments Data

Brian Weis, MD

Internal Medicine · Amarillo, TXNPI 1801827449

Payments from drug & device makers

$678in general payments, 2019–2025

Across 32 payments — averaging $21.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$302
  • Gilead$250
  • AbbVie$60
  • Novartis$31
  • Theratechnologies Inc.$20
  • Ferring Pharmaceuticals Inc.$15

What the payments were for

  • Food & beverage$65897%
  • Education$203%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$678 in reported general payments places this provider in the 60th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$27,890
Medicare patients
131
Services billed
338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala416$1,679,142
DescovyEmtricitabine/Tenofov Alafenam39$94,128
JulucaDolutegravir/Rilpivirine19$71,536
TivicayDolutegravir Sodium25$60,412
TriumeqAbacavir/Dolutegravir/Lamivudi13$46,615
IsentressRaltegravir Potassium14$31,852
EliquisApixaban26$14,631
XareltoRivaroxaban17$11,598
SymbicortBudesonide/Formoterol Fumarate28$5,851
Celecoxib58$2,529
Acetaminophen-CodeineAcetaminophen With Codeine94$2,149
BreynaBudesonide/Formoterol Fumarate11$1,498
Gabapentin118$1,222
Ventolin HfaAlbuterol Sulfate22$1,153
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen25$956

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$250$1,773,270455 claims
Viiv Healthcare CompanyJuluca, Tivicay, Triumeq$302$178,56357 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Amarillo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →